Literature DB >> 1720040

Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells.

H Ikeda1, Y Kanakura, T Tamaki, A Kuriu, H Kitayama, J Ishikawa, Y Kanayama, T Yonezawa, S Tarui, J D Griffin.   

Abstract

The c-kit proto-oncogene encodes a receptor tyrosine kinase that is thought to play an important role in hematopoiesis. In a series of human acute myeloblastic leukemia (AML), the expression of the c-kit proto-oncogene and its product was studied by means of Northern blot and immunoblot analyses. The c-kit mRNA was expressed in 20 of 25 cases of AML, and in those cases the product of the c-kit proto-oncogene was detected by immunoblotting with anti-c-kit antibody. The expression of c-kit transcripts and protein was barely detectable in normal bone marrow cells as a control. The expression of c-kit transcript did not correlate with the French-American-British classification nor clinical manifestations. In 6 of 11 cases that expressed c-kit product, AML cells were found to proliferate in response to recombinant human stem cell factor (rhSCF), the ligand for c-kit, and the synergistic stimulation of AML cells was observed by rhSCF and granulocyte-macrophage colony-stimulating factor. Immunoblotting with anti-phosphotyrosine antibody showed that the c-kit receptor protein was detectably phosphorylated in 7 of 12 cases tested before the stimulation with rhSCF, while the rhSCF treatment resulted in an increased tyrosine phosphorylation of c-kit in AML cells. These results indicate that c-kit proto-oncogene is expressed in most cases of AML and is functional in terms of supporting proliferation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1720040

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  53 in total

1.  KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice.

Authors:  Ling Zhao; Jan J Melenhorst; Lemlem Alemu; Martha Kirby; Stacie Anderson; Maggie Kench; Shelley Hoogstraten-Miller; Lauren Brinster; Yasuhiko Kamikubo; D Gary Gilliland; P Paul Liu
Journal:  Blood       Date:  2011-12-07       Impact factor: 22.113

2.  Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.

Authors:  Xiaoyang Li; Yuqi Jiang; Yuri K Peterson; Tongqiang Xu; Richard A Himes; Xin Luo; Guilin Yin; Elizabeth S Inks; Nathan Dolloff; Stephanie Halene; Sherine S L Chan; C James Chou
Journal:  J Med Chem       Date:  2020-05-06       Impact factor: 7.446

3.  Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia.

Authors:  Akane Tsujimura; Hitoshi Kiyoi; Yukimasa Shiotsu; Yuichi Ishikawa; Yumiko Mori; Hiroshi Ishida; Tsutomu Toki; Etsuro Ito; Tomoki Naoe
Journal:  Int J Hematol       Date:  2010-10-05       Impact factor: 2.490

Review 4.  Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic.

Authors:  Muneera Al-Hussaini; John F DiPersio
Journal:  Expert Rev Hematol       Date:  2014-08       Impact factor: 2.929

5.  SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain.

Authors:  M Kozlowski; L Larose; F Lee; D M Le; R Rottapel; K A Siminovitch
Journal:  Mol Cell Biol       Date:  1998-04       Impact factor: 4.272

6.  Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia.

Authors:  Shujun Liu; Lai-Chu Wu; Jiuxia Pang; Ramasamy Santhanam; Sebastian Schwind; Yue-Zhong Wu; Christopher J Hickey; Jianhua Yu; Heiko Becker; Kati Maharry; Michael D Radmacher; Chenglong Li; Susan P Whitman; Anjali Mishra; Nicole Stauffer; Anna M Eiring; Roger Briesewitz; Robert A Baiocchi; Kenneth K Chan; Peter Paschka; Michael A Caligiuri; John C Byrd; Carlo M Croce; Clara D Bloomfield; Danilo Perrotti; Ramiro Garzon; Guido Marcucci
Journal:  Cancer Cell       Date:  2010-04-13       Impact factor: 31.743

Review 7.  Integration of hypoxic HIF-α signaling in blood cancers.

Authors:  L Schito; S Rey; M Konopleva
Journal:  Oncogene       Date:  2017-05-22       Impact factor: 9.867

8.  FIP1L1-PDGFRalpha imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells.

Authors:  Kentaro Fukushima; Itaru Matsumura; Sachiko Ezoe; Masahiro Tokunaga; Masato Yasumi; Yusuke Satoh; Hirohiko Shibayama; Hirokazu Tanaka; Atsushi Iwama; Yuzuru Kanakura
Journal:  J Biol Chem       Date:  2009-01-14       Impact factor: 5.157

9.  Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.

Authors:  T Furitsu; T Tsujimura; T Tono; H Ikeda; H Kitayama; U Koshimizu; H Sugahara; J H Butterfield; L K Ashman; Y Kanayama
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

10.  High-Resolution Mapping of RNA Polymerases Identifies Mechanisms of Sensitivity and Resistance to BET Inhibitors in t(8;21) AML.

Authors:  Yue Zhao; Qi Liu; Pankaj Acharya; Kristy R Stengel; Quanhu Sheng; Xiaofan Zhou; Hojoong Kwak; Melissa A Fischer; James E Bradner; Stephen A Strickland; Sanjay R Mohan; Michael R Savona; Bryan J Venters; Ming-Ming Zhou; John T Lis; Scott W Hiebert
Journal:  Cell Rep       Date:  2016-08-04       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.